PD-1

[Life Sciences] Scientists inhibited two of the most important immune checkpoints expressed on T cells infiltrated in tumors, including PD-1 and A2aR. Ligation of PD-1 with PD-L1 and A2aR with adenosine significantly suppress T cell responses against tumor cells.

[BMC Medicine] The effect of combined SFN and CAR-T cells was determined in vitro using a co-culture system and in vivo using a xenograft mouse model. They furthered validated the effects of combination therapy in patients with cancer.

[Critical Reviews in Oncology Hematology] The authors conduct a meta-analysis, showing that the addition of programmed death-1/programmed death ligand-1 (PD-L1) blockade to chemotherapy improves progression-free survival in PD-L1 positive metastatic TNBC patients, also in the intention-to-treat population.

[Cancer Immunology Research] The authors showed that expression of the axon guidance molecule PlexinA4 in cytotoxic T cell, especially in effector/memory CD8+ T cells, was induced upon T cell activation, sustained in the circulation, but reduced when entering the tumor bed.

[Cancer Immunology Research] Transcriptome analysis revealed that B7-H3 was highly expressed in PD-L1-low, non-immunoreactive high-grade serous ovarian cancer tumors, and its expression negatively correlated with an IFNγ signature, which reflected the tumor immune-reactivity.

[Journal For Immunotherapy of Cancer] Autologous tumor organoids were stimulated with T cells from the patients’ peripheral blood for two weeks to generate the organoid-primed T cells.